Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	PhaseBio Pharmaceuticals	Anebulo Pharmaceuticals	Matinas BioPharma	Equillium	ObsEva
Symbol	NASDAQ:PHAS	NASDAQ:ANEB	NYSEAMERICAN:MTNB	NASDAQ:EQ	NASDAQ:OBSV
Price Information
Current Price	$3.69	$7.01	$0.72	$5.41	$2.47
50-Day Moving Average	$3.62	$7.39	$1.11	$6.10	$2.89
52-Week Low	$2.60	$6.31	$0.66	$3.47	$1.86
52-Week High	$5.83	$9.33	$2.22	$13.50	$5.55
MarketRank™
Overall Score	1.6	1.7	1.2	1.6	1.2
Analysis Score	3.5	3.5	3.4	3.5	3.3
Community Score	2.3	5.0	2.8	4.6	2.3
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.0	0.0	0.0
Earnings & Valuation Score	0.6	0.0	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$11.00	$15.00	$3.38	$14.80	$15.33
% Upside from Price Target	198.10% upside	113.98% upside	369.34% upside	173.57% upside	520.78% upside
Trade Information
Market Cap	$167.67 million	$163.61 million	$146.90 million	$157.11 million	$142.15 million
Beta	1.63	N/A	2.57	1.61	0.76
Average Volume	300,230	6,007	913,795	96,535	444,115
Sales & Book Value
Annual Revenue	$320,000.00	N/A	$160,000.00	N/A	$20,000.00
Price / Sales	523.98	N/A	918.11	N/A	7,107.43
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	($0.86) per share	N/A	$0.30 per share	$2.82 per share	$0.15 per share
Price / Book	-4.29	N/A	2.40	N/A	16.47
Profitability
Net Income	$-98,570,000.00	$170,000.00	$-22,450,000.00	$-29,810,000.00	$-82,970,000.00
EPS	($3.39)	N/A	($0.12)	($1.46)	($1.67)
Trailing P/E Ratio	N/A	0.00	N/A	N/A	N/A
Forward P/E Ratio	N/A	∞	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	N/A
Return on Equity (ROE)	-3,182.40%	N/A	-34.95%	-45.74%	-312.89%
Return on Assets (ROA)	-158.49%	N/A	-30.09%	-37.66%	-98.06%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.64%	N/A	N/A	0.08%	0.51%
Current Ratio	5.29%	N/A	28.43%	14.37%	4.29%
Quick Ratio	5.29%	N/A	28.43%	14.37%	4.29%
Ownership Information
Institutional Ownership Percentage	70.18%	N/A	19.34%	26.28%	30.68%
Insider Ownership Percentage	9.00%	N/A	7.80%	32.70%	N/A
Miscellaneous
Employees	50	2	20	31	42
Shares Outstanding	45.44 million	23.34 million	204.28 million	29.04 million	57.55 million
Next Earnings Date	8/10/2021 (Estimated)	9/20/2021 (Estimated)	8/9/2021 (Estimated)	8/11/2021 (Estimated)	8/5/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	ObsEva SA (NASDAQ: OBSV) Declined -17.94% Over The Last Month - Are There Ways To Succeed From This Decline? - Marketing Sentinel marketingsentinel.com - July 24 at 11:03 AM
	Dysmenorrhea Market Projected to Show Strong Growth 2028 \| AbbVie/ Neurosciences Biosciences, Nobelpharma/ASKA Pharmaceutical, ObsEva – The Manomet Current - The Manomet Current manometcurrent.com - July 20 at 8:00 PM
	ObsEva SA (NASDAQ:OBSV) Expected to Announce Earnings of -$0.26 Per Share americanbankingnews.com - July 19 at 11:34 AM
	ObsEva SA (NASDAQ: OBSV): Is This The Time To Buy? - Marketing Sentinel marketingsentinel.com - July 17 at 8:37 AM
	Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock? - Yahoo Finance finance.yahoo.com - July 12 at 2:29 PM
	Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock? finance.yahoo.com - July 12 at 2:29 PM
	Global Menstrual Cramps Treatment Market Worldwide Opportunities, Driving Forces, Future Potential 2028\|\|PMS4PMS, LLC, Sanofi, Nobelpharma Co., Ltd., ObsEva, Myovant Sciences Ltd., AbbVie Inc., BioElectronics Corporation – The Manomet Current - The Manomet Current manometcurrent.com - July 5 at 9:06 AM
	ObsEva SA (NASDAQ:OBSV) Receives Consensus Rating of "Hold" from Brokerages americanbankingnews.com - July 3 at 2:24 PM
	ObsEva (NASDAQ:OBSV) Given Buy Rating at Wedbush americanbankingnews.com - July 3 at 1:28 PM
	Short Interest in ObsEva SA (NASDAQ:OBSV) Drops By 31.0% americanbankingnews.com - July 2 at 4:00 PM
	ObsEva to Present Ebopiprant (OBE022) Data at the Society - GlobeNewswire globenewswire.com - July 2 at 1:26 PM
	ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting - Yahoo Finance finance.yahoo.com - July 2 at 8:26 AM
	ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty - GlobeNewswire globenewswire.com - June 30 at 8:45 AM
	ObsEva SA (NASDAQ:OBSV) Stock Forecast: up to 24 USD! stocksregister.com - June 27 at 1:23 AM
	ObsEva To Present Data on Two Clinical Development Programs - GlobeNewswire globenewswire.com - June 24 at 9:48 AM
	Do Hedge Funds Love ObsEva SA (OBSV)? - Yahoo Finance finance.yahoo.com - June 15 at 12:19 AM
	Do Hedge Funds Love ObsEva SA (OBSV)? finance.yahoo.com - June 14 at 7:18 PM
	ObsEva SA (NASDAQ:OBSV) Stock Gains Momentum After The News: Will The Rally Continue? - DRP Gazette drpgazette.com - June 10 at 10:35 PM
	ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on - GlobeNewswire globenewswire.com - June 10 at 1:10 AM
	ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021 finance.yahoo.com - June 10 at 1:10 AM
	Abnormal Uterine Bleeding (AUB) Market Soaring Demands by 2028 with ObsEva, Bayer, AbbVie, Myovant Sciences, AbbVie, Enteris BioPharma, Ferring Pharmaceuticals – The Manomet Current - The Manomet Current manometcurrent.com - June 8 at 6:09 PM
	Ready for Takeoff? ObsEva SA (NASDAQ:OBSV) Is In News - DRP Gazette drpgazette.com - June 2 at 12:57 PM
	ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021 - Yahoo Finance finance.yahoo.com - June 2 at 7:51 AM
	ObsEva SA Announces that Shareholders Approved all Board - GlobeNewswire globenewswire.com - May 31 at 9:59 AM
	ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021 benzinga.com - May 31 at 1:16 AM

Date	Company	Brokerage	Action
7/14/2021	Equillium	HC Wainwright	Reiterated Rating
7/2/2021	ObsEva	Wedbush	Reiterated Rating
6/17/2021	PhaseBio Pharmaceuticals	Needham & Company LLC	Lower Price Target
6/15/2021	Equillium	SVB Leerink	Reiterated Rating
5/25/2021	Anebulo Pharmaceuticals	Benchmark	Initiated Coverage
5/18/2021	Equillium	SVB Leerink	Reiterated Rating
5/11/2021	Matinas BioPharma	Piper Sandler	Downgrade
4/1/2021	Equillium	SVB Leerink	Reiterated Rating
3/30/2021	Matinas BioPharma	HC Wainwright	Reiterated Rating
3/18/2021	PhaseBio Pharmaceuticals	Stifel Nicolaus	Reiterated Rating
3/16/2021	PhaseBio Pharmaceuticals	Needham & Company LLC	Boost Price Target
3/3/2021	Equillium	Jonestrading	Initiated Coverage
2/15/2021	Matinas BioPharma	Aegis	Reiterated Rating
2/9/2021	Equillium	HC Wainwright	Reiterated Rating
1/29/2021	Matinas BioPharma	Maxim Group	Reiterated Rating
1/12/2021	ObsEva	Wedbush	Reiterated Rating
1/12/2021	ObsEva	SVB Leerink	Boost Price Target
1/4/2021	Matinas BioPharma	Piper Sandler	Boost Price Target
1/4/2021	ObsEva	HC Wainwright	Lower Price Target
11/30/2020	Equillium	HC Wainwright	Lower Price Target
11/30/2020	Equillium	HC Wainwright	Reiterated Rating
11/9/2020	ObsEva	JPMorgan Chase & Co.	Downgrade
11/6/2020	Matinas BioPharma	Maxim Group	Initiated Coverage
10/5/2020	ObsEva	HC Wainwright	Lower Price Target
9/21/2020	Equillium	HC Wainwright	Reiterated Rating
8/25/2020	PhaseBio Pharmaceuticals	Citigroup	Lower Price Target
8/21/2020	Equillium	HC Wainwright	Lower Price Target
8/14/2020	ObsEva	Wedbush	Reiterated Rating
8/13/2020	Matinas BioPharma	Aegis	Boost Price Target
8/13/2020	Equillium	Jefferies Financial Group	Reiterated Rating
8/11/2020	PhaseBio Pharmaceuticals	Stifel Nicolaus	Reiterated Rating
8/11/2020	Matinas BioPharma	HC Wainwright	Reiterated Rating
8/10/2020	Equillium	Stifel Nicolaus	Reiterated Rating
7/13/2020	Equillium	HC Wainwright	Reiterated Rating
7/13/2020	Equillium	Stifel Nicolaus	Reiterated Rating
7/7/2020	ObsEva	SVB Leerink	Lower Price Target
7/7/2020	ObsEva	JPMorgan Chase & Co.	Downgrade
7/6/2020	ObsEva	BMO Capital Markets	Downgrade
7/1/2020	ObsEva	HC Wainwright	Reiterated Rating
7/1/2020	ObsEva	Wedbush	Reiterated Rating
6/5/2020	ObsEva	HC Wainwright	Reiterated Rating
6/2/2020	Matinas BioPharma	Aegis	Reiterated Rating
5/29/2020	PhaseBio Pharmaceuticals	Citigroup	Boost Price Target
5/28/2020	PhaseBio Pharmaceuticals	Needham & Company LLC	Initiated Coverage
5/26/2020	Equillium	HC Wainwright	Reiterated Rating
5/23/2020	Matinas BioPharma	Maxim Group	Initiated Coverage
5/19/2020	Equillium	HC Wainwright	Reiterated Rating
5/13/2020	Matinas BioPharma	Maxim Group	Reiterated Rating
5/5/2020	PhaseBio Pharmaceuticals	Stifel Nicolaus	Reiterated Rating
5/5/2020	ObsEva	Wedbush	Reiterated Rating
4/6/2020	PhaseBio Pharmaceuticals	Citigroup	Lower Price Target
4/1/2020	Matinas BioPharma	Maxim Group	Initiated Coverage
3/27/2020	Equillium	HC Wainwright	Reiterated Rating
3/23/2020	ObsEva	Wedbush	Reiterated Rating
3/23/2020	ObsEva	HC Wainwright	Lower Price Target
3/6/2020	Matinas BioPharma	Maxim Group	Reiterated Rating
3/5/2020	ObsEva	Wedbush	Boost Price Target
1/26/2020	Matinas BioPharma	Piper Sandler	Initiated Coverage
1/23/2020	Matinas BioPharma	SunTrust Banks	Initiated Coverage
1/21/2020	ObsEva	Wedbush	Reiterated Rating
1/21/2020	ObsEva	HC Wainwright	Reiterated Rating
1/9/2020	Matinas BioPharma	Aegis	Initiated Coverage
1/2/2020	Equillium	SVB Leerink	Reiterated Rating
12/30/2019	Equillium	HC Wainwright	Reiterated Rating
12/20/2019	PhaseBio Pharmaceuticals	HC Wainwright	Reiterated Rating
12/20/2019	Matinas BioPharma	HC Wainwright	Reiterated Rating
12/19/2019	ObsEva	HC Wainwright	Reiterated Rating
12/10/2019	ObsEva	Royal Bank of Canada	Boost Price Target
12/2/2019	ObsEva	HC Wainwright	Reiterated Rating
11/8/2019	ObsEva	Credit Suisse Group	Downgrade
10/31/2019	ObsEva	Wedbush	Reiterated Rating
10/11/2019	ObsEva	Wedbush	Set Price Target
10/3/2019	PhaseBio Pharmaceuticals	HC Wainwright	Initiated Coverage
9/26/2019	Matinas BioPharma	Maxim Group	Reiterated Rating
9/24/2019	PhaseBio Pharmaceuticals	Cowen	Reiterated Rating
9/11/2019	PhaseBio Pharmaceuticals	William Blair	Reiterated Rating
9/9/2019	PhaseBio Pharmaceuticals	Stifel Nicolaus	Lower Price Target
8/14/2019	Matinas BioPharma	HC Wainwright	Reiterated Rating
8/13/2019	Equillium	HC Wainwright	Reiterated Rating
7/12/2019	Equillium	HC Wainwright	Initiated Coverage
7/2/2019	Equillium	HC Wainwright	Initiated Coverage
6/26/2019	Matinas BioPharma	HC Wainwright	Reiterated Rating
6/26/2019	Matinas BioPharma	HC Wainwright	Initiated Coverage
5/24/2019	PhaseBio Pharmaceuticals	Citigroup	Set Price Target
5/17/2019	Matinas BioPharma	BTIG Research	Initiated Coverage
5/16/2019	Matinas BioPharma	Maxim Group	Reiterated Rating
2/22/2019	Equillium	SVB Leerink	Reiterated Rating
2/11/2019	Matinas BioPharma	Roth Capital	Reiterated Rating
2/11/2019	Matinas BioPharma	Roth Capital	Initiated Coverage
11/13/2018	PhaseBio Pharmaceuticals	Needham & Company LLC	Initiated Coverage
11/12/2018	PhaseBio Pharmaceuticals	Cowen	Initiated Coverage
11/12/2018	PhaseBio Pharmaceuticals	Citigroup	Initiated Coverage
11/12/2018	PhaseBio Pharmaceuticals	Stifel Nicolaus	Initiated Coverage
11/6/2018	Equillium	Jefferies Financial Group	Initiated Coverage
11/6/2018	Equillium	Stifel Nicolaus	Initiated Coverage

(Data available from 7/25/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources